Splicing factor ESRP1 controls ER-positive breast cancer by altering metabolic pathways

Yesim Polar, Yaseswini Neelamraju, Chirayu P. Goswami, Yuan Gu, Xiaoping Gu, Gouthami Nallamothu, Edyta Vieth, Sarath C. Janga, Michael Ryan, Sunil Badve

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The epithelial splicing regulatory proteins 1 and 2 (ESRP1 and ESRP2) control the epithelial-to-mesenchymal transition (EMT) splicing program in cancer. However, their role in breast cancer recurrence is unclear. In this study, we report that high levels of ESRP1, but not ESRP2, are associated with poor prognosis in estrogen receptor positive (ER+) breast tumors. Knockdown of ESRP1 in endocrine-resistant breast cancer models decreases growth significantly and alters the EMT splicing signature, which we confirm using TCGA SpliceSeq data of ER+ BRCA tumors. However, these changes are not accompanied by the development of a mesenchymal phenotype or a change in key EMT-transcription factors. In tamoxifen-resistant cells, knockdown of ESRP1 affects lipid metabolism and oxidoreductase processes, resulting in the decreased expression of fatty acid synthase (FASN), stearoyl-CoA desaturase 1 (SCD1), and phosphoglycerate dehydrogenase (PHGDH) at both the mRNA and protein levels. Furthermore, ESRP1 knockdown increases the basal respiration and spare respiration capacity. This study reports a novel role for ESRP1 that could form the basis for the prevention of tamoxifen resistance in ER+ breast cancer.

Original languageEnglish (US)
Article numbere46078
JournalEMBO Reports
Volume20
Issue number2
DOIs
StatePublished - Feb 1 2019

Fingerprint

Tamoxifen
Metabolic Networks and Pathways
Epithelial-Mesenchymal Transition
Tumors
Phosphoglycerate Dehydrogenase
Stearoyl-CoA Desaturase
Breast Neoplasms
Fatty Acid Synthases
Estrogen Receptors
Oxidoreductases
Respiration
Proteins
Transcription Factors
Protein Splicing
Messenger RNA
Lipid Metabolism
Neoplasms
Phenotype
Recurrence
RNA Splicing Factors

Keywords

  • alternative splicing
  • ER-positive breast cancer
  • ESRP1
  • fatty acid metabolism
  • HTA

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Genetics

Cite this

Splicing factor ESRP1 controls ER-positive breast cancer by altering metabolic pathways. / Polar, Yesim; Neelamraju, Yaseswini; Goswami, Chirayu P.; Gu, Yuan; Gu, Xiaoping; Nallamothu, Gouthami; Vieth, Edyta; Janga, Sarath C.; Ryan, Michael; Badve, Sunil.

In: EMBO Reports, Vol. 20, No. 2, e46078, 01.02.2019.

Research output: Contribution to journalArticle

Polar, Y, Neelamraju, Y, Goswami, CP, Gu, Y, Gu, X, Nallamothu, G, Vieth, E, Janga, SC, Ryan, M & Badve, S 2019, 'Splicing factor ESRP1 controls ER-positive breast cancer by altering metabolic pathways', EMBO Reports, vol. 20, no. 2, e46078. https://doi.org/10.15252/embr.201846078
Polar, Yesim ; Neelamraju, Yaseswini ; Goswami, Chirayu P. ; Gu, Yuan ; Gu, Xiaoping ; Nallamothu, Gouthami ; Vieth, Edyta ; Janga, Sarath C. ; Ryan, Michael ; Badve, Sunil. / Splicing factor ESRP1 controls ER-positive breast cancer by altering metabolic pathways. In: EMBO Reports. 2019 ; Vol. 20, No. 2.
@article{753e8a797c564c28984d5e9efdbeb617,
title = "Splicing factor ESRP1 controls ER-positive breast cancer by altering metabolic pathways",
abstract = "The epithelial splicing regulatory proteins 1 and 2 (ESRP1 and ESRP2) control the epithelial-to-mesenchymal transition (EMT) splicing program in cancer. However, their role in breast cancer recurrence is unclear. In this study, we report that high levels of ESRP1, but not ESRP2, are associated with poor prognosis in estrogen receptor positive (ER+) breast tumors. Knockdown of ESRP1 in endocrine-resistant breast cancer models decreases growth significantly and alters the EMT splicing signature, which we confirm using TCGA SpliceSeq data of ER+ BRCA tumors. However, these changes are not accompanied by the development of a mesenchymal phenotype or a change in key EMT-transcription factors. In tamoxifen-resistant cells, knockdown of ESRP1 affects lipid metabolism and oxidoreductase processes, resulting in the decreased expression of fatty acid synthase (FASN), stearoyl-CoA desaturase 1 (SCD1), and phosphoglycerate dehydrogenase (PHGDH) at both the mRNA and protein levels. Furthermore, ESRP1 knockdown increases the basal respiration and spare respiration capacity. This study reports a novel role for ESRP1 that could form the basis for the prevention of tamoxifen resistance in ER+ breast cancer.",
keywords = "alternative splicing, ER-positive breast cancer, ESRP1, fatty acid metabolism, HTA",
author = "Yesim Polar and Yaseswini Neelamraju and Goswami, {Chirayu P.} and Yuan Gu and Xiaoping Gu and Gouthami Nallamothu and Edyta Vieth and Janga, {Sarath C.} and Michael Ryan and Sunil Badve",
year = "2019",
month = "2",
day = "1",
doi = "10.15252/embr.201846078",
language = "English (US)",
volume = "20",
journal = "EMBO Reports",
issn = "1469-221X",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Splicing factor ESRP1 controls ER-positive breast cancer by altering metabolic pathways

AU - Polar, Yesim

AU - Neelamraju, Yaseswini

AU - Goswami, Chirayu P.

AU - Gu, Yuan

AU - Gu, Xiaoping

AU - Nallamothu, Gouthami

AU - Vieth, Edyta

AU - Janga, Sarath C.

AU - Ryan, Michael

AU - Badve, Sunil

PY - 2019/2/1

Y1 - 2019/2/1

N2 - The epithelial splicing regulatory proteins 1 and 2 (ESRP1 and ESRP2) control the epithelial-to-mesenchymal transition (EMT) splicing program in cancer. However, their role in breast cancer recurrence is unclear. In this study, we report that high levels of ESRP1, but not ESRP2, are associated with poor prognosis in estrogen receptor positive (ER+) breast tumors. Knockdown of ESRP1 in endocrine-resistant breast cancer models decreases growth significantly and alters the EMT splicing signature, which we confirm using TCGA SpliceSeq data of ER+ BRCA tumors. However, these changes are not accompanied by the development of a mesenchymal phenotype or a change in key EMT-transcription factors. In tamoxifen-resistant cells, knockdown of ESRP1 affects lipid metabolism and oxidoreductase processes, resulting in the decreased expression of fatty acid synthase (FASN), stearoyl-CoA desaturase 1 (SCD1), and phosphoglycerate dehydrogenase (PHGDH) at both the mRNA and protein levels. Furthermore, ESRP1 knockdown increases the basal respiration and spare respiration capacity. This study reports a novel role for ESRP1 that could form the basis for the prevention of tamoxifen resistance in ER+ breast cancer.

AB - The epithelial splicing regulatory proteins 1 and 2 (ESRP1 and ESRP2) control the epithelial-to-mesenchymal transition (EMT) splicing program in cancer. However, their role in breast cancer recurrence is unclear. In this study, we report that high levels of ESRP1, but not ESRP2, are associated with poor prognosis in estrogen receptor positive (ER+) breast tumors. Knockdown of ESRP1 in endocrine-resistant breast cancer models decreases growth significantly and alters the EMT splicing signature, which we confirm using TCGA SpliceSeq data of ER+ BRCA tumors. However, these changes are not accompanied by the development of a mesenchymal phenotype or a change in key EMT-transcription factors. In tamoxifen-resistant cells, knockdown of ESRP1 affects lipid metabolism and oxidoreductase processes, resulting in the decreased expression of fatty acid synthase (FASN), stearoyl-CoA desaturase 1 (SCD1), and phosphoglycerate dehydrogenase (PHGDH) at both the mRNA and protein levels. Furthermore, ESRP1 knockdown increases the basal respiration and spare respiration capacity. This study reports a novel role for ESRP1 that could form the basis for the prevention of tamoxifen resistance in ER+ breast cancer.

KW - alternative splicing

KW - ER-positive breast cancer

KW - ESRP1

KW - fatty acid metabolism

KW - HTA

UR - http://www.scopus.com/inward/record.url?scp=85060333732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060333732&partnerID=8YFLogxK

U2 - 10.15252/embr.201846078

DO - 10.15252/embr.201846078

M3 - Article

C2 - 30665944

AN - SCOPUS:85060333732

VL - 20

JO - EMBO Reports

JF - EMBO Reports

SN - 1469-221X

IS - 2

M1 - e46078

ER -